College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
College of Acupuncture and Massage, Shandong University of Traditional Chinese Medicine, Jinan, China.
Medicine (Baltimore). 2024 Mar 22;103(12):e37305. doi: 10.1097/MD.0000000000037305.
Chronic urticaria is a group of skin diseases characterized by pruritus and/or vascular oedema and belongs to the category of "addictive rash" in Traditional Chinese Medicine, and its aetiology is closely related to wind evil. Antihistamines are often used in treatment. Although they have certain effects, they also easily cause disease recurrence. Xiaofeng powder treats this disease has a significant effect in improving the disease state and reducing the recurrence rate. However, there is a lack of evidencebased research. This study to systematically evaluate the clinical efficacy of modified Xiaofeng powder in the treatment of chronic urticaria (CU).
Computer searches of Chinese databases such as China National Knowledge Infrastructure, China Scientific Journal Database, China Biomedical Literature Database, and WanFang Date and foreign databases such as PubMed and the Web of Science were performed. We retrieved published clinical randomized controlled trials of Xiaofeng powder in the treatment of CU from the establishment of the databases to November 2023. The data were extracted from clinical trials that met the inclusion criteria of this study, and the quality was evaluated through the Cochrane Handbook of Systematic Reviews 5.1.0. Finally, a meta-analysis was performed using RevMan 5.3 statistical software.
A total of 11 randomized controlled trials involving 1076 patients were included. The cure rate odds ratio (OR) and 95% confidence interval (CI; shown in brackets) were 2.11 [1.45, 3.07]; the total effective rate OR and CI were 2.42 [1.60, 3.68]; the recurrence rate OR and CI were 0.22 [0.15, 0.34]; the adverse reaction rate OR and CI were 0.23 [0.12, 0.45]; and the mean weighted mean difference (MD) and 95% CI (shown in brackets) of itching degree, wind mass size, wind mass number and wind mass duration in symptom and sign integrals were -0.70 [-0.73, 0.67], -0.64 [-0.96, 0.31], , -0.72 [-1.23, 0.22], and -0.68 [-1.13, 0.23], , respectively.
The clinical efficacy of modified Xiaofeng powder in the treatment of CU is better than that of antihistamine drugs, with lower adverse reaction and recurrence rates and higher safety. However, the quality of clinical research included is relatively low, and findings need to be confirmed by high-quality research.
慢性荨麻疹是一组以瘙痒和/或血管性水肿为特征的皮肤病，属于中医“瘾疹”范畴，其病因与风邪密切相关。治疗常使用抗组胺药。虽然它们有一定的效果，但也容易导致疾病复发。消风散治疗本病在改善病情和降低复发率方面有显著效果。然而，缺乏循证医学研究。本研究旨在系统评价消风散加减治疗慢性荨麻疹（CU）的临床疗效。
计算机检索中国知网、中国科技期刊数据库、中国生物医学文献数据库、万方数据等中文数据库，以及 PubMed 和 Web of Science 等外文数据库，检索建库至 2023 年 11 月发表的消风散治疗 CU 的临床随机对照试验。从符合纳入标准的临床试验中提取数据，并通过 Cochrane 系统评价手册 5.1.0 评价质量。最后，使用 RevMan 5.3 统计软件进行荟萃分析。
共纳入 11 项随机对照试验，涉及 1076 例患者。治愈率优势比（OR）和 95%置信区间（CI；括号内显示）为 2.11[1.45，3.07]；总有效率 OR 和 CI 为 2.42[1.60，3.68]；复发率 OR 和 CI 为 0.22[0.15，0.34]；不良反应率 OR 和 CI 为 0.23[0.12，0.45]；症状和体征积分瘙痒程度、风团大小、风团个数和风团持续时间的均数差值（MD）及 95%CI（括号内显示）分别为-0.70[-0.73，0.67]、-0.64[-0.96，0.31]、、-0.72[-1.23，0.22]和-0.68[-1.13，0.23]、、。
消风散加减治疗 CU 的临床疗效优于抗组胺药，不良反应和复发率较低，安全性较高。但是，纳入的临床研究质量相对较低，需要高质量的研究来证实这些发现。
